适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 3,500
- 主要终点
- Safety, as determined by adverse events, laboratory data, physical examination and ECG.
研究概览
简要总结
The purpose of this study is to assess the long term safety of Crestor.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Completion of previous Crestor study as listed in the protocol.
排除标准
- •Pregnant or breast feeding women, or not using appropriate contraception.
- •Abnormal lab values as listed in the protocol.
研究组 & 干预措施
1
Experimental
Rosuvastatin
干预措施: Rosuvastatin (Drug)
结局指标
主要结局
Safety, as determined by adverse events, laboratory data, physical examination and ECG.
时间窗: 12 weekly
次要结局
- Success in achieving goals for Cholesterol levels(12 weekly)
研究者
相似试验
已完成
2 期
An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Subjects With Alagille Syndrome (ALGS)Alagille SyndromeNCT02047318Mirum Pharmaceuticals, Inc.19
已完成
2 期
A Long-term (12 Months) Safety, Tolerability and Efficacy Study of LCZ696 in Patients With Essential HypertensionEssential HypertensionNCT01256411Novartis Pharmaceuticals341
已完成
3 期
Long-term Extension Study of the Safety, Tolerability, and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-36)Chronic Obstructive Pulmonary DiseaseNCT00970268AstraZeneca291
已完成
3 期
Evaluating the Safety of Etanercept in the Treatment of Psoriasis in Adult SubjectsPsoriasisNCT00111436Amgen912
进行中（未招募）
3 期
Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia VeraPolycythemia VeraNCT06033586Protagonist Therapeutics, Inc.46